Pharmaspectra receives funding from private equity firm, Inflexion.
The rise of these predatory journals has largely been driven by the “publish or perish” dictum predominant in academia, where careers, promotions, and funding can depend on publishing research. To identify these problematic publications, look for these hallmarks
Where to Publish Drug Trial Results? Traditional Journal Rankings Fail to Deliver their Promised Impact
While such impact scores have their merits for the authors themselves — whose paychecks, reputations, grants, and very careers notoriously depend on the journals they reach and the citations received in their wake — those types of quantitative metrics only tell half the story for Medical Affairs professionals
At a high level, providers are concerned with two primary considerations: cost and quality.